HbA1c Variation Study

Inclusion Criteria:

1. Subject must have type 1 or type 2 diabetes.

2. Subject is at least 4 years old.

3. Point-of-care (POC) HbA1C of 3.0%-15.5% (9 mmol/mol - 146 mmol/mol)

4. Subject must be able to read and understand English.

5. In the investigator's opinion, the subject must be able to follow the instructionsprovided to him/her by the study site and perform all study tasks as specified bythe protocol.

6. Subject must be available to participate in all study visits.

7. Subject must be willing and able to provide written signed and dated informedconsent.

8. Subjects age 4 - 17: Parent or guardian must be willing and able to provide writtensigned and dated informed consent.

9. Subjects age 11 - 17 Subject must be willing and able to provide written signed anddated informed assent.

Exclusion Criteria:

10. Subject is currently undergoing dialysis or planning to receive dialysis during thecourse of the study

11. History of blood transfusion in the last 3 months or planned blood transfusionduring the course of the study.

12. Subject is currently planning to undergo a major medical intervention expected tosignificantly alter red cell life span, i.e. chemotherapy, major surgery requiringblood transfusions, etc.

13. Subject has known allergy to medical grade adhesive or isopropyl alcohol used todisinfect skin.

14. Subjects age 18 and older: Subject is known to be pregnant, attempting to conceiveor is not willing and able to practice birth control during the study duration study (applicable to female subjects only). Subjects age 17 and younger: Subject is knownto be pregnant at the time of study enrollment or is planning to become pregnantduring the study (applicable to female subjects only).

15. Subject has extensive skin changes/diseases at the proposed application sites thatcould interfere with device placement or the accuracy of interstitial glucosemeasurements. Such conditions include, but are not limited to extensive psoriasis,recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitisherpetiformis, skin lesions, redness, infection or edema.

16. Subject has a pacemaker or any other neurostimulators.

17. Subject has concomitant medical condition which, in the opinion of the investigator,could present a risk to the safety or welfare of the subject or study staff.

18. Subject is currently participating in another interventional clinical trial.

19. Subject is unsuitable for participation due to any other cause as determined by theInvestigator.